http://purl.org/np/RAm1N3XVLrnUPDbCsyK-RRoP8G70BZp4mxX0Nae0_sJtA#Head http://purl.org/np/RAm1N3XVLrnUPDbCsyK-RRoP8G70BZp4mxX0Nae0_sJtA http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAm1N3XVLrnUPDbCsyK-RRoP8G70BZp4mxX0Nae0_sJtA#assertion http://purl.org/np/RAm1N3XVLrnUPDbCsyK-RRoP8G70BZp4mxX0Nae0_sJtA http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAm1N3XVLrnUPDbCsyK-RRoP8G70BZp4mxX0Nae0_sJtA#provenance http://purl.org/np/RAm1N3XVLrnUPDbCsyK-RRoP8G70BZp4mxX0Nae0_sJtA http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAm1N3XVLrnUPDbCsyK-RRoP8G70BZp4mxX0Nae0_sJtA#pubinfo http://purl.org/np/RAm1N3XVLrnUPDbCsyK-RRoP8G70BZp4mxX0Nae0_sJtA http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAm1N3XVLrnUPDbCsyK-RRoP8G70BZp4mxX0Nae0_sJtA#assertion http://purl.obolibrary.org/obo/DOID_10763 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAm1N3XVLrnUPDbCsyK-RRoP8G70BZp4mxX0Nae0_sJtA#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_10763 http://purl.org/np/RAm1N3XVLrnUPDbCsyK-RRoP8G70BZp4mxX0Nae0_sJtA#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAm1N3XVLrnUPDbCsyK-RRoP8G70BZp4mxX0Nae0_sJtA#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00678 http://purl.org/np/RAm1N3XVLrnUPDbCsyK-RRoP8G70BZp4mxX0Nae0_sJtA#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAm1N3XVLrnUPDbCsyK-RRoP8G70BZp4mxX0Nae0_sJtA#association http://www.w3.org/2000/01/rdf-schema#label losartan potassium tablet usp is an angiotensin ii receptor blocker arb indicated for treatment of hypertension to lower blood pressure in adults and children greater than 6 years old lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions 1 1 reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy there is evidence that this benefit does not apply to black patients 1 2 treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension 1 3 losartan potassium tablets usp are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older to lower blood pressure lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular cv events primarily strokes and myocardial infarction these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan control of high blood pressure should be part of comprehensive cardiovascular risk management including as appropriate lipid control diabetes management antithrombotic therapy smoking cessation exercise and limited sodium intake many patients will require more than 1 drug to achieve blood pressure goals for specific advice on goals and management see published guidelines such as those of the national high blood pressure education program s joint national committee on prevention detection evaluation and treatment of high blood pressure jnc numerous antihypertensive drugs from a variety of pharmacologic classes and with different mechanisms of action have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality and it can be concluded that it is blood pressure reduction and not some other pharmacologic property of the drugs that is largely responsible for those benefits the largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly elevated systolic or diastolic pressure causes increased cardiovascular risk and the absolute risk increase per mmhg is greater at higher blood pressures so that even modest reductions of severe hypertension can provide substantial benefit relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk so the absolute benefit is greater in patients who are at higher risk independent of their hypertension for example patients with diabetes or hyperlipidemia and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal some antihypertensive drugs have smaller blood pressure effects as monotherapy in black patients and many antihypertensive drugs have additional approved indications and effects e g on angina heart failure or diabetic kidney disease these considerations may guide selection of therapy losartan potassium tablets usp may be administered with other antihypertensive agents losartan potassium tablets usp are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy but there is evidence that this benefit does not apply to black patients see use in specific populations 8 6 and clinical pharmacology 12 3 losartan potassium tablets usp are indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria urinary albumin to creatinine ratio 3 mg g in patients with type 2 diabetes and a history of hypertension in this population losartan potassium tablet usp reduces the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end stage renal disease need for dialysis or renal transplantation see clinical studies 14 3 http://purl.org/np/RAm1N3XVLrnUPDbCsyK-RRoP8G70BZp4mxX0Nae0_sJtA#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAm1N3XVLrnUPDbCsyK-RRoP8G70BZp4mxX0Nae0_sJtA#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAm1N3XVLrnUPDbCsyK-RRoP8G70BZp4mxX0Nae0_sJtA#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB00678 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAm1N3XVLrnUPDbCsyK-RRoP8G70BZp4mxX0Nae0_sJtA#provenance http://purl.org/np/RAm1N3XVLrnUPDbCsyK-RRoP8G70BZp4mxX0Nae0_sJtA#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAm1N3XVLrnUPDbCsyK-RRoP8G70BZp4mxX0Nae0_sJtA#pubinfo http://purl.org/np/RAm1N3XVLrnUPDbCsyK-RRoP8G70BZp4mxX0Nae0_sJtA#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAm1N3XVLrnUPDbCsyK-RRoP8G70BZp4mxX0Nae0_sJtA#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAm1N3XVLrnUPDbCsyK-RRoP8G70BZp4mxX0Nae0_sJtA#sig http://purl.org/nanopub/x/hasSignature HBGwAxLBeqSpBUCqnqZBerG05QlFBjSJkSvHooRhzwB/w1SRyt50XHtHCH0KTgZDONI4aRdfSzsKjnRbUjhDEc6Awj9n8CB/kXl2ZVYqY/A7hGS1Lw/5E5eSnRmtQA3C3dW+/GSSyXJUhkRWuUNfts3RAtUJEQ4/xP1kRTEkTz8= http://purl.org/np/RAm1N3XVLrnUPDbCsyK-RRoP8G70BZp4mxX0Nae0_sJtA#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAm1N3XVLrnUPDbCsyK-RRoP8G70BZp4mxX0Nae0_sJtA http://purl.org/np/RAm1N3XVLrnUPDbCsyK-RRoP8G70BZp4mxX0Nae0_sJtA http://purl.org/dc/terms/created 2021-06-27T19:57:25.087+02:00 http://purl.org/np/RAm1N3XVLrnUPDbCsyK-RRoP8G70BZp4mxX0Nae0_sJtA http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAm1N3XVLrnUPDbCsyK-RRoP8G70BZp4mxX0Nae0_sJtA https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAm1N3XVLrnUPDbCsyK-RRoP8G70BZp4mxX0Nae0_sJtA https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAm1N3XVLrnUPDbCsyK-RRoP8G70BZp4mxX0Nae0_sJtA https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs